Harrow Health Q3 2025 Earnings Preview

* Harrow Health (HROW [https://seekingalpha.com/symbol/HROW]) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close.
* The consensus EPS Estimate is $0.29 [https://seekingalpha.com/symbol/HROW/earnings/estimates] (+680.0% Y/Y) and the consensus Revenue Estimate is $73.7M (+49.6% Y/Y).
* Over the last 2 years, HROW has beaten EPS estimates [https://seekingalpha.com/symbol/HROW/earnings/eps-surprise-summary] 38% of the time and has beaten revenue estimates 38% of the time.
* Over the last 3 months, EPS estimates have seen 1 upward revision [https://seekingalpha.com/symbol/HROW/earnings/revisions] and 2 downward. Revenue estimates have seen 1 upward revision and 6 downward.
* Recent earnings Analysis from our contributors:Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential [https://seekingalpha.com/article/4838356-harrow-q3-earnings-preview-this-business-has-eye-popping-potential]

MORE ON HARROW HEALTH

* Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential [https://seekingalpha.com/article/4838356-harrow-q3-earnings-preview-this-business-has-eye-popping-potential]
* Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other [https://seekingalpha.com/article/4830251-harrow-stock-positive-negative-adjustments-after-investor-day-offset-each-other]
* Harrow, Inc. (HROW) Analyst/Investor Day Transcript [https://seekingalpha.com/article/4826299-harrow-inc-hrow-analyst-investor-day-transcript]
* Harrow to buy Melt Pharmaceuticals [https://seekingalpha.com/news/4499432-harrow-to-buy-melt-pharmaceuticals]
* Harrow launches $250M debt offering [https://seekingalpha.com/news/4493008-harrow-launches-250m-debt-offering]